NL-OMON47099尚未招募不适用
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in Subjects with Advanced Solid Tumors - CA012-004 phase 1/2a of BMS-986178alone and with Nivolumab and Ipilimumab
Bristol-Myers Squibb0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting;• ECOG (Eastern Cooperative Oncology Group) 0-1;• Men and women 18 years old or older;• At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
排除标准
- •Known central nervous system metastases or central nervous system as the only source of disease;• Concomitant malignancies;• Active known or suspected autoimmune disease;• Uncontrolled or significant cardiovascular disease;• Major surgery less than 4 weeks before the start of the study
研究者
相似试验
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumaband/or Ipilimumab in Subjects With Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2015-004816-39-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO166
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors.EUCTR2015-004816-39-NLBristol-Myers Squibb International Corporation166
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 19.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2015-004816-39-ESBristol-Myers Squibb International Corporation245
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-000603-91-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO235
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2016-000603-91-DEBristol-Myers Squibb International Corporation246